Search Results

You are looking at 1 - 6 of 6 items for :

  • All content x
Clear All

Three molecular markering techniques: inter-simple sequence repeat (ISSR); start codon targeted (SCoT), conserved DNA-derived polymorphism (CDDP) markers were compared for fingerprinting of 40 varieties of bread wheat. The number of scoreable and polymorphic bands produced using the ISSR, SCoT and CDDP primers for varieties was more than that of genotypes. Average polymorphism information content (PIC) for ISSR, SCoT and CDDP markers was 0.39, 0.41 and 0.34, respectively, and this revealed that three different marker types were equal for the assessment of diversity amongst genotypes. Cluster analysis for three different molecular types revealed that genotypes taken for the analysis can be divided in three and four distinct clusters. There were no significant differences among these markers in terms of the evaluation of genotypes. These results suggest that efficiency of SCoT, CDDP and ISSR markers was relatively the same in fingerprinting of genotypes but SCoT and CDDP analysis are more effective in fingerprinting of wheat genotypes. To our knowledge, this was the first detailed report of a comparison of performance among two targeted DNA region molecular markers (SCoT and CDDP) in comparision with ISSR technique on a set of samples of wheat cultivars. Overall, our results indicate that SCoT, ISSR and CDDP fingerprinting could be used to detect polymorphism for genotypes of wheat.

Restricted access

Abstract  

The proposal of this work was to investigate the effect of the radioactive (NH3)2PtCl2, cis-diamminedichloroplatinum (II) or CDDP* on malignant glioma cells and verify if the low-dose continuous internal radio-chemotherapy would be able to produce additive effects. The antitumoral activity of CDDP* and the non labeled cisplatin, CDDP, were evaluated in glioblastoma. Cisplatin was cytotoxic for glioblastoma cells in a dose dependent manner. Treatment with CDDP*, (IC50 = 1.75 ± 0.07 μM), proved to be more potent than using just CDDP, (IC50 = 4.96 ± 0.40 μM). These results suggest that cisplatin is a very potent radiosensitizer evoking a supra additive effect. Internal radio-chemotherapy treatment based on CDDP* may be useful alternative to reduce the drug concentration required for effective inhibition of glioblastoma growth.

Restricted access

Abstract  

An improved method is described for the synthesis of195mPt-radiolabelled cis-diamminedichloroplatinum/II. An amount of 10 mg of 95% enriched194Pt was irradiated for 75 h in the hydraulic conveyer of the KUR at a thermal neutron flux of approximately 8.15×1013 n.cm–2.sec–1 and the195mPt-radiolabelled CDDP was purified using HPLC. The chemical yield is 61% its chemical purity is greater than 99.74% the radiochemical purity is nearly 100%, and the specific activity is 7.4×106 Bq mg–1 CDDP/200 Ci mg–1 CDDP/.

Restricted access

Abstract  

The literature indicates that the interaction of Tb3+ with DNA modified by the antitumour drug cis-diaminedichloroplatinum(II) (CDDP) results in substantial enhancement of the fluorescence of this cation, while no enhancement is observed in the case of DNA modified by irradiation with ionizing radiation. This study investigates the effect of Tb3+ on the survival of cultured mammalian cells treated with CDDP. HeLa cells were treated with a combination of195mPt-CDDP and TbCl3, and the relationship between lethal effect and the numbers of Tb and/or Pt atoms binding to DNA, RNA and proteins was examined. The Tb content in each fraction was determined using instrumental neutron activation analysis. It was found that the cytotoxic effect of CDDP was greatly enhanced by the presence of Tb ions (D0 of CDDP fell from 8.3 μM without Tb to 3.2 μM with 0.75 mM Tb), while no such effect was found in radiation-induced cell-killing. The number of Tb atoms bound to DNA molecules in a cell was calculated to be about 4.5·107, namely 1 per 1.400 nucleotides, under that situation.

Restricted access

Abstract  

Cisplatin (CDDP) is an antineoplastic drug used in the treatment of a wide variety of tumors. This paper describes an investigation carried out on pregnant mice after intragastric or intraperitoneally treatment with CDDP from day 11 to 13 of gestation. Platinum content in different tissues, namely liver, kidney, placenta and brain, was determined at 18 day of pregnancy. Two analytical techniques were used, i.e. neutron activation analysis and atomic absorption spectroscopy. Results of both techniques are presented and discussed in terms of precision, accuracy and sensitivity. Neutron activation analysis appears to provide results better correlated with the drug treatment.

Restricted access

of platinum complexes: Cisplatin (CDDP), Carboplatin (CBDCA) and Iproplatin (CHIP) Cancer Chemother Pharmacol 21 40 44 . 17

Restricted access